Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing first-in-class immunology, immuno-oncology, and anti-addiction therapeutics. Omeros' pipeline is led by its complement franchise of protein and orally available small-molecule drug candidates targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of complement, and MASP-3, the key activator of the alternative pathway.
Endothelial injury syndromes (EIS) resulting from hematopoietic stem cell transplant (HSCT) encompass numerous serious and potentially fatal complications. Endothelial injury, including HSCT-TMA, can occur prior to, during, and after HSCT.